id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-4020-0008,FDA,FDA-2015-E-4020,Letter from U.S. Patent and Trademark Office to Boehringer Ingelheim Corporation,Other,Letter(s),2020-09-08T04:00:00Z,2020,9,2020-09-08T04:00:00Z,,2020-09-08T19:48:27Z,,0,0,090000648484b351
FDA-2015-E-4020-0007,FDA,FDA-2015-E-4020,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2019-03-07T05:00:00Z,2019,3,2019-03-07T05:00:00Z,,2019-03-07T16:53:57Z,,0,0,0900006483acaa5f
FDA-2015-E-4020-0006,FDA,FDA-2015-E-4020,"Determination of Regulatory Review Period for Purposes of Patent
Extension; OFEV",Notice,Determinations,2018-02-22T05:00:00Z,2018,2,2018-02-22T05:00:00Z,2018-04-24T03:59:59Z,2018-02-22T18:48:32Z,2018-03606,0,0,0900006482f51f57
FDA-2015-E-4020-0005,FDA,FDA-2015-E-4020,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-07T04:00:00Z,2017,6,2017-06-07T04:00:00Z,,2017-06-07T16:41:25Z,,0,0,09000064826a26f6
FDA-2015-E-4020-0004,FDA,FDA-2015-E-4020,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T16:32:03Z,,0,0,0900006482434387
FDA-2015-E-4020-0003,FDA,FDA-2015-E-4020,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-12-17T05:00:00Z,2015,12,2015-12-17T05:00:00Z,,2015-12-17T16:12:48Z,,0,0,0900006481db7910
FDA-2015-E-4020-0002,FDA,FDA-2015-E-4020,Letter from the U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-11-02T05:00:00Z,2015,11,2015-11-02T05:00:00Z,,2015-11-02T17:05:29Z,,0,0,0900006481d03bb8
FDA-2015-E-4020-0001,FDA,FDA-2015-E-4020,Patent Extension Application from Boehringer Ingelheim Corporation (on behalf of Boehringer Ingelheim Pharma GmbH & KG.),Other,Application,2015-11-02T05:00:00Z,2015,11,2015-11-02T05:00:00Z,,2015-11-02T17:04:22Z,,0,0,0900006481d03bb7